Skip Ribbon Commands
Skip to main content
Sign In



New Collaboration with StafaCT Will Optimize Patient Pathways for Cellular Treatments

Terumo BCT Announces Enrollment of the First Patient in Its U.S. Clinical Trial Designed to Study Platelets Treated With the Mirasol® Pathogen Reduction Technology (PRT) System

Collaborative Global Effort to Advance Blood Safety Moves Forward Across Ghana

Terumo BCT's Spectra Optia® Apheresis System Is the First and Only Device on the European Market Indicated to Treat Guillain-Barré Syndrome and Myasthenia Gravis using Therapeutic Plasma Exchange